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Sphingolipid activator proteins (SAPs) are non-enzy-
matic glycoproteins required for lysosomal degradation
of various sphingolipids with short oligosaccharide
chains by their respective exohydrolases. Four of these
(SAP-A to SAP-D or saposins A to D) are derived from a
common precursor by proteolytic processing. Alterna-
tive splicing of the SAP-precursor gene results in inser-
tion of additional 6 or 9 bases of exon 8* or 8, respec-
tively, into the SAP-B coding region of the transcribed
mRNAs.
To examine the features of the three different SAP-
precursor proteins (prosaposins), the respective cDNAs
were stably expressed in baby hamster kidney cells.
Pulse-chase experiments with transfected cells and en-
docytosis studies on human fibroblasts showed that syn-
thesis, transport, and maturation of all SAP-precursor
led to formation of the four mature SAPs (SAP-A to
SAP-D).
In order to determine the biological function of the
three different SAP-B isoforms, SAP-precursor-deficient
human fibroblasts were loaded with recombinant SAP-
precursor proteins with or without 2- and 3-amino acid
insertions, respectively, purified from the medium of
the baby hamster kidney cells. They were found to stim-
ulate at nanomolar concentrations the turnover of bio-
synthetically labeled ceramide, glucosylceramide, and
lactosylceramide. Since the physiological function of
SAP-B is to stimulate the degradation of sulfatide by
arylsulfatase A (EC 3.1.6.1) and globotriaosylceramide
by b-galactosidase (EC 3.2.1.23) loading studies with the
respective exogenously labeled lipids on SAP-precursor-
deficient fibroblasts were performed. Addition of differ-
ent purified SAP-precursors to the medium of the lipid-
loaded fibroblasts showed positive stimulation of the
lipid degradation by all three SAP-B isoforms derived
from the SAP-precursors. These findings establish that
all three forms of the SAP-B can function as sulfatide/
globotriaosylceramide activator.
The physiological degradation of glycosphingolipids with
short oligosaccharide chains is catalyzed by lysosomal exohy-
drolases in the presence of small, heat-stable glycoproteins, so
called sphingolipid activator proteins (SAPs)1 or saposins (1).
Four of the five known activator proteins (SAP-A to SAP-D or
saposins A–D) are derived from a common precursor polypep-
tide by proteolytic processing (2, 3). This precursor also called
prosaposin was identified as a protein of 68 kDa in human skin
fibroblasts by studying the synthesis and processing of SAP-C
(4). After modification of its N-linked oligosaccharides in the
Golgi apparatus, a 73-kDa form is secreted into the culture
medium. Processing to the mature polypeptides of 8–13 kDa
takes place after the transport of the precursor to the acidic
organelles of the cells.
Although different activating properties for the SAPs (SAP-A
to SAP-D) have been described, their physiological relevance
has been established only for SAP-B and SAP-C (1). The ab-
sence of SAP-C in human patients with Gaucher disease shows
the relevance of this activator protein for the degradation of
glucosylceramide by glucosylceramidase (EC 3.2.1.45) (1, 5).
While SAP-A is known to stimulate the breakdown of several
glycosphingolipids in vitro (6, 7), SAP-D has recently been
shown to be involved in ceramide degradation in vivo (8). This
was established in an in vivo test system, in which the break-
down of [14C]serine-labeled sphingolipids accumulating in hu-
man fibroblasts derived from patients with SAP-precursor de-
ficiency (9) was stimulated by addition of different SAPs
(SAP-A to SAP-D) to the culture medium.
SAP-B itself has capacity to bind several sphingolipids, but
its genetic defect leads to an accumulation of sulfatides, glo-
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The abbreviated designations of the gangliosides are according to Sven-
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L. (1963) J. Neurochem. 10, 613–623). To date there are different
nomenclatures used throughout the literature for the sphingolipid ac-
tivator proteins and their precursor protein: sphingolipid activator pro-
tein precursor 5 prosaposin or SAP-precursor; sphingolipid activator
proteins A–D: saposin A 5 SAP-A, saposin B 5 SAP-B, saposin C 5
SAP-C, and saposin D 5 SAP-D. In this article we use the designation
SAP-precursor, SAP-A, SAP-B, SAP-C, and SAP-D for the correspond-
ing proteins.
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botriaosylceramide, digalactosylceramide, and ganglioside GM3
in a disorder classified as metachromatic leukodystrophy
(1, 10).
The SAP-precursor gene localized on the long arm of human
chromosome 10 (10q21–22) (11) consists of at least 15 exons,
four of which (exon 6–9) code for SAP-B. Exon 8 consists of only
9 base pairs (12) and can be spliced differentially, generating
three different cDNAs (13, 14): one containing all 9 bases of
exon 8, one containing the downstream 6 bases of exon 8 (also
called exon 89) and one completely lacking this exon (Fig. 1). At
the protein level, only SAP-B without the amino acids derived
from exon 8 has been detected so far (10, 15). A recent report
shows a differential tissue distribution of the mRNAs with or
without exon 8 in different cell lines or tissues (16). The mul-
tiple mRNA species were also detected in the mouse (17). These
findings prompt the question whether the different sequences
within the SAP-B domain in the SAP-precursor have any bio-
logical significance. In the present report we describe the ex-
pression and processing of the three SAP-precursor forms in
BHK cells stably transfected with the respective cDNAs. In
addition, the stimulation of sulfatide and globotriaosylceram-
ide degradation by the three SAP-B isoforms was tested in vivo
in a cell culture system by adding purified recombinant pre-
cursor proteins (designated as SAP-precursor 0, 6, or 9) to the
medium of lipid loaded human SAP-precursor-deficient
fibroblasts.
EXPERIMENTAL PROCEDURES
Materials—Restriction and modifying enzymes were purchased from
Boehringer Mannheim (Mannheim, Federal Republic of Germany), Life
Technologies, Inc. (Eggenstein, Federal Republic of Germany), and New
England Biolabs (Schwalbach, Federal Republic of Germany). Peptide-
N-glycanase F and Endo H were from New England Biolabs (Schwal-
bach, Federal Republic of Germany). Radiolabeled chemicals were ob-
tained from Amersham Corp. (Braunschweig, Federal Republic of
Germany). Culture media for bacterial and eukaryotic cells were from
Life Technologies, Inc., Biochrom (Berlin, Federal Republic of Ger-
many), Sigma (Deisenhofen, Federal Republic of Germany), and ICN
(Meckenheim, Federal Republic of Germany). Fetal calf serum was
purchased from Cytogen (Berlin, Federal Republic of Germany). Puro-
mycin was from Sigma (Deisenhofen, Federal Republic of Germany)
and G418 sulfate from Life Technologies, Inc. Protein A-Sepharose was
obtained from Sigma, and protein G-agarose was from Calbiochem-
Novabiochem (Bad Soden, Federal Republic of Germany).
All other commercially available materials were obtained from the
following suppliers: Sigma, Merck (Darmstadt, Federal Republic of
Germany), Pharmacia LKB Biotechnologies (Freiburg, Federal Repub-
lic of Germany), and New England Biolabs.
[3H]Sulfatide, which was labeled in the sphingoid moiety, and
[3H]globotriaosylceramide labeled in the terminal galactosyl residue
were synthesized in our laboratory according to published procedures
(18, 19).
Antisera—Human SAP-A and SAP-C were purified from spleen of a
Gaucher patient essentially as described earlier (8, 20). Polyclonal
anti-SAP-A and anti-SAP-C antisera were raised in rabbits by injection
of 100 mg of pure protein in combination with Freund’s complete adju-
vant followed by three booster injections of 100 mg protein each in
Freund’s incomplete adjuvant given in 4-week intervals. The animals
were bled 10 days after the final injection. The antisera had ELISA titer
of 1:950 and 1:900 (half-maximal A405 of 3-fold serum dilutions on a
50-ng antigen coat) against SAP-A and SAP-C, respectively. Specificity
of the antisera was assessed by ELISA, immunoblot and immunopre-
cipitation, and in the case of the anti-SAP-C antiserum by comparison
with the rabbit anti-SAP-C antiserum described earlier (21).
The preparation of the goat anti-SAP-B and anti-SAP-D antisera has
been described earlier (8).
Cells and Cell Culture—Human skin fibroblasts and baby hamster
kidney cells (BHK 21 ATCC CCC 10) were maintained at 37 °C in 5%
CO2 in Dulbecco’s modified Eagle’s medium supplemented with antibi-
otics, 4.5 mM NaHCO3 and 10% fetal calf serum (FCS) as described
previously (22). Transfected BHK cells were routinely cultured in me-
dium additionally supplemented with 5 mg/ml puromycin. The fibro-
blasts from a SAP-precursor deficient human fetus have been described
earlier (9, 23, 24).
Expression of the SAP-precursor Proteins in BHK Cells—The expres-
sion plasmid pBHE9 was constructed by placing the entire SAP-pre-
cursor cDNA (from nucleotide -9 to 1597, numbered from A of the ATG
initiation codon) which contained the 9 base pairs of exon 8 into the
XbaI and SmaI site downstream of the SV40 early promoter in the
expression vector pBHE (25). The expression plasmid pBHE0 contain-
ing the SAP-precursor cDNA without exon 8 and the expression plas-
mid pBHE6 containing the cDNA with the 6 bases of exon 89 were
constructed by replacing nucleotides 543 to 797 (using the Bsu36I and
BglII restriction sites on the precursor cDNAs) in the expression plas-
mid pBHE9 by the respective cDNA segments of the other SAP-precur-
sor cDNAs. These cDNA segments were derived from partial cDNAs
obtained by reverse transcriptase-polymerase chain reaction of total
RNA isolated from human fibroblasts (9). The correct cDNA sequence of
each expression plasmids pBHE0, pBHE6, and pBHE9 was confirmed
by DNA sequencing (26).
Stably transfected BHK cells were obtained by cotransfection of the
expression plasmids and of the plasmids pSV2 pac and pSV2 neo
conferring resistance to puromycin and G418 sulfate to the cells (27), as
described previously (28). BHK cells transfected only with the expres-
sion plasmid pBHE were used as control.
Processing and Endocytosis Studies—Confluent cultures of trans-
fected BHK cells in 25-cm2 tissue culture flasks were incubated for 1 h
in 1 ml of methionine-free modified Eagle’s medium (MEM) containing
4% dialyzed and heat-inactivated FCS. The cells were labeled by incu-
bation in 0.7 ml of this medium supplemented with 1.85 MBq of
FIG. 1. Relationship of SAP-B to the
human SAP-precursor gene (accord-
ing to Ref. 14). a, structure of the human
SAP-precursor gene, which occupies
about 20 kb of the long arm of chromo-
some 10. Open boxes correspond to exons
2–15 covering the cDNA sequence from
the codon Ala14 to the end. Black areas
correspond to untranslated regions. The
putative exon 1 (in brackets) which should
cover the missing 59 end of the gene has
not yet been identified. b, the SAP-precur-
sor cDNA. Exons and untranslated re-
gions are indicated as in a. c, the SAP-
precursor protein (527 amino acids).
Domains A–D correspond to the mature
activator proteins A–D. N-Glycosylation
sites are marked by the closed circles. d,
mature SAP-B. The mature SAP-B is en-
coded on exons 6–9 of the prosaposin
gene. Alternative forms of SAP-B are en-
coded by different mRNA species gener-
ated by splicing exon 7 either to exon 8 or
to the last 6 bases of exon 8 (exon 89) or
directly to exon 9.
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L-[35S]methionine (specific radioactivity . 37 TBq/mmol) for 1 h. The
chase periods were started by addition of unlabeled methionine (final
concentration 10 mM). For endocytosis studies, 0.7 ml of medium from
transfected BHK cells labeled for 5 h with 2.5 MBq of L-[35S]methionine
was added to 1.3 ml of culture medium of human SAP-precursor-
deficient fibroblasts and the media were supplemented with unlabeled
methionine to a final concentration of 10 mM. The fibroblasts were
maintained for 24 h in this medium.
Cell extracts were prepared with phosphate-buffered saline contain-
ing 1% Nonidet P-40, 10 mM EDTA, 2 mM phenylmethanesulfonyl
fluoride, 1 mM pepstatin A and leupeptin each. Immunoprecipitations
using the corresponding anti-SAP-antisera were performed as de-
scribed previously (9). Deglycosylation of the precipitated proteins with
peptide-N-glycanase F and Endo H was performed according to the
manufacturer’s instructions. Immunoprecipitated proteins were ana-
lyzed by SDS-polyacrylamide gel electrophoresis using gradient gels
(7–17%). The gels were impregnated with Amplify for fluorography and
exposed to the Kodak X-Omat AR film.
Isolation and Purification of Recombinant SAP-precursor Proteins—
The three different SAP-precursor differing in the additional amino
acids encoded by exon 8 or 89 were purified from the medium (Dif
1000-medium, 0.1% FCS) of the BHK cells transfected with the corre-
sponding cDNA according to published procedures (29). The purifica-
tion of the proteins was monitored by immunoblotting and ELISA.
Metabolic Labeling of Sphingolipids by [14C]Serine—Human fibro-
blasts were preincubated for 24 h with MEM containing 0.6% FCS and
SAP-precursor 0, 6, or 9 as indicated. Subsequently the medium was
exchanged against medium supplemented with 0.3% FCS and
[14C]serine (1 mCi/ml medium, 54 Ci/mol). After 24 h the medium was
removed and replaced by a medium containing L-serine (185 nmol/ml
medium), 0.6% FCS, and the same concentrations of the SAP-precursor
0, 6, or 9 as during the preincubation period. After 120 h of chase the
cells were harvested by trypsinization.
Sulfatide- and Globotriaosylceramide Loading Studies—Sulfatide
and globotriaosylceramide loading studies were performed by modifica-
tions of published procedures (30, 31). In brief, the fibroblasts were
preincubated for 24 h with MEM containing 10% FCS and the purified
SAP-precursor 0, 6, or 9 (0.5 mg/ml medium) as indicated. Then the
medium was exchanged with MEM supplemented with 10% FCS and
[3H]sulfatide (3.3 nmol/ml medium, 86 Ci/mol) or [3H]globotriaosylcer-
amide (1.35 nmol/ml medium, 180 Ci/mol). After 48 h of loading, the
cells were incubated for additional 120 h in MEM containing the same
supplements as during the preincubation period. Subsequently the cells
were harvested by trypsinization.
Isolation of Cellular Sphingolipids—Cellular sphingolipids were iso-
lated and identified as described previously (8). In brief, the lipids were
extracted from the cell pellets with 7 ml of chloroform/methanol/water/
pyridine (60:160:6:1 by volume) for 24 h at 50 °C. Phospholipids were
degraded by mild alkaline hydrolysis with methanolic NaOH (50 mM)
for 2 h at 37 °C. Then, the lipid extracts were desalted by reversed-
phase chromatography (32). For the [14C]serine-labeled lipids, samples
were applied to TLC plates on the bases of equal amounts of radioac-
tivity, while for the loading studies, samples were chromatographed on
the basis of amounts of protein (estimated after homogenization of the
cells). In both instances, the solvent system was chloroform/methanol/
0.22% aqueous CaCl2 (60:35:8 by volume). All glycosphingolipids were
identified from their RF values. Radioactive spots were quantified using
a Fuji BAS 1000 phosphorimaging system and the TINA program
(version 2.07). They were visualized by autoradiography.
Other Methods—Proteins were assayed with bovine serum albumin
as standard using the bicinchoninic acid assay (33).
Presentation of Data—Radioactivity of individual sphingolipids is
expressed as percentage of total radioactivity of the sphingolipid frac-
tion. Total radioactivity is normalized to the same amount of cellular
protein. All data are given as means of at least two separate
experiments.
RESULTS
Expression and Maturation of the Three Different SAP-pre-
cursor Forms in BHK Cells—In order to follow synthesis and
transport of the different SAP-precursor isoforms and their
maturation in cell culture, stably transfected BHK cells were
prepared. Metabolic labeling of transfected BHK cells with
[35S]methionine and immunoprecipitation of the expressed pro-
teins from the cell extracts with an anti-SAP-C antiserum
revealed that after 1 h of pulse labeling a SAP-precursor of
apparent 68 kDa was generated by all three cDNA forms (Fig.
2). Additionally processed forms of about 46 and 30 kDa were
detectable. Within 2 h of chase there was significant biosyn-
thesis of radiolabeled mature SAP-C with an apparent mass of
13 kDa. This protein was further processed to 11- to 8-kDa
forms during an additional chase of 18 h. The major immuno-
precipitable protein, secreted into the culture media, was the
SAP-precursor with an apparent molecular mass of 73 kDa,
which was already detectable after 1 h of pulse. In addition,
processed proteins of molecular masses of 46 and 30 kDa were
precipitable from the media, presumably identical with the tri-
and disaposin forms described earlier in expression of a SAP-
FIG. 2. Biosynthesis of the SAP-precursor isoforms in transfected BHK cells. BHK cells transfected either with the expression plasmids
pBHE0, pBHE6, pBHE9, or only the vector pBHE without a cDNA insertion as a control (Co) were pulsed with [35S]methionine for 1 h and chased
for the times indicated. SAP-precursors and SAP-C from the cell extracts and the media were immunoprecipitated using a rabbit anti-SAP-C
antiserum and were analyzed by denaturing gel electrophoresis and fluoropgraphy. A faint band at 46 kDa, detectable only in the immunopre-
cipitations of the cell extracts and denoted by an asterisk, is caused by unspecific contaminations of immunoprecipitates.
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precursor in insects cells (27). During the pulse and chase
periods more than 60% of the immunoprecipitable proteins
were secreted into the medium of the transfected cells. Secre-
tion of the 73-kDa forms started 30 min after a short pulse
labeling of 5 min (data not shown). No cross-reacting material
was precipitated from extracts of control BHK cells (Fig. 2, Co).
This labeling experiment indicated formation of similar
polypeptides in BHK cells transfected with the different SAP-
precursor cDNAs as described for in human fibroblasts (4). The
different amounts of immunoprecipitable proteins in the trans-
fected BHK cells were due to the fact that the totality of BHK
cells resistant to the antibiotics were used for pulse-chase
experiments and that the selection leaves varying numbers of
non-resistant cells.
In order to assess correct processing of all three different
recombinant SAP-precursor to the four mature SAPs (SAP-A to
SAP-D) and to analyze their carbohydrate structures, the BHK
transfectants were metabolically labeled for 5 h, and the cell
extracts were subjected to immunoprecipitation with poly-
clonal antisera against the corresponding mature SAP-A to
SAP-D (Fig. 3). All three SAP-precursors resulted in formation
of mature SAP-A, SAP-B, SAP-C, and SAP-D, differing with
respect to their carbohydrate types as analyzed previously (34,
35). In our hands, mature SAP-A never yielded a clear band in
its glycosylated form, but only a broad patch ranging from 14.5
to 29 kDa. Upon deglycosylation, however, a clear band com-
parible in size with deglycosylated mature SAP-B, SAP-C, and
SAP-D was obtained. The carbohydrate chains of SAP-A were
Endo H-resistant, presumably being of the complex type,
whereas the carbohydrate moieties of SAP-C and SAP-D were
predominantly of the Endo H-sensitive high mannose or hybrid
type. It is noteworthy that each SAP-precursor generated a
mature SAP-B with an Endo H-resistant carbohydrate chain.
Endocycosis of the SAP-precursor Isoforms—To confirm that
human cells process the three SAP-precursors in the same
manner as the BHK transfectants, BHK cells were labeled with
[35S]methionine, and the medium containing the secreted pro-
teins was added to human fibroblasts derived from a SAP-
precursor-deficient fetus (9). After a 24-h incubation the media
and cell extracts were analyzed for immunoprecipitable SAP-B,
SAP-C, and SAP-D with the corresponding antisera (Fig. 4).
Some SAP-precursor was still detectable in the medium. About
50% of each of the different radiolabeled SAP-precursor forms
had been internalized by the SAP-precursor deficient fibro-
blasts and processed to the mature SAP-A to SAP-D. Repeating
the endocytosis experiment with normal human fibroblasts
showed an uptake of about 30% of each prosaposin form and
the same correct processing to the mature proteins (data not
shown). Thus, no difference with regard to maturation was
observed for any of the three SAP-precursors in human fibro-
blasts in comparison with BHK cells.
Purification of the SAP-precursor Isoforms—The three differ-
ent isoforms of the recombinant SAP-precursors were purified
from the medium of transfected BHK cells by a two-step pro-
cedure as described for the purification of SAP-precursor ex-
pressed in insect cells (29). Affinity chromatography on a con-
canavalin A-Sepharose was performed, followed by reversed-
phase chromatography. Since not only the SAP-precursor
forms of 73 kDa, but also processed forms of 46 and 30 kDa,
were detectable in the medium of the transfected BHK cells
(Fig. 2), it was not surprising that all these proteins were
copurified from the media. A separation of these protein forms
was not achieved under the chosen high performance liquid
chromatography conditions. The three precursor isoforms
showed mutually identical elution profiles with no significant
difference in retention time. The purification progress was
monitored by ELISA and immunoblots using an anti-SAP-D
antiserum, which confirmed that the 46- and 30-kDa forms
were also SAP-precursor forms (data not shown). Due to the
different expression efficiencies of the BHK cells the yield of
purified proteins varied among the different transfected BHK
FIG. 4. Endocytosis of SAP-precursor isoforms by cultured hu-
man fibroblasts from a patient with SAP-precursor deficiency.
Medium from [35S]methionine-labeled BHK cells transfected with the
SAP-precursor cDNA isoforms (pBHE0, pBHE6, and pBHE9) or with
the expression plasmid pBHE (Co) were added to the culture medium of
unlabeled fibroblasts derived from a patient with SAP-precursor defi-
ciency. After 24 h the fibroblasts were harvested and analyzed for
internalized immunoprecipitable SAP-B, SAP-C, and SAP-D. Immuno-
precipitations were carried out from the media with an anti-SAP-C
antiserum and from the cell extracts with the antisera indicated. As-
terisk, the faint bands visible in the control precipitation with the
anti-SAP-D antiserum presumable arose from endogenous BHK cell
SAP-precursor cross-reacting with this antiserum.
FIG. 3. Immunoprecipitation andN-
glycosylation analysis of all mature
SAPs (SAP-A to SAP-D) from trans-
fected BHK cells. The BHK cells trans-
fected with the expression plasmids
pBHE0, pBHE6, and pBHE9 were labeled
with [35S]methionine for 5 h. The mature
SAPs (SAP-A to SAP-D) were immuno-
precipitated with the corresponding anti-
sera as indicated and treated either with
peptide-N-glycanase F (PNGase F) or
Endo H as described under “Experimen-
tal Procedures.”
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cells. The yields were 15 mg/liter medium for SAP-precursor0,
55 mg/liter for SAP-precursor6, and 150 mg/liter for SAP-pre-
cursor9, respectively. When the medium of BHK control cells
was subjected to the same purification procedure, no immuno-
logically cross-reactive material and no significant amount of
other proteins were detected in the fractions, which should
have contained the expression products. Nevertheless, these
fractions were pooled to serve as control (Co) in the further
experiments to eliminate the influence of the endogenous BHK
proteins.
Effect of the SAP-precursor 0, 6, or 9 on the Lipid Turnover in
Human Fibroblasts—Metabolic labeling of sphingolipids with
[14C]serine in cultured human fibroblasts followed by a long
chase period resulted in labeling of the most prominent sphin-
golipids of normal fibroblasts, sphingomyelin, and globosides,
while in fibroblasts derived from a patient affected with SAP-
precursor deficiency an increased labeling of the storage com-
pounds characteristic for this disease, e.g. ceramide, glucosyl-
ceramide, lactosylceramide, and ganglioside GM3, occurred
(Fig. 5). Since it had become clear from the endocytosis exper-
iments that the SAP-precursor isoforms were taken up and
processed effectively, we attempted to restore the lipid metab-
olism in the mutant fibroblasts by administration of recombi-
nant SAP-precursors. The cells were preincubated and chased
for 120 h in the presence of different concentrations (from 0.025
to 0.9 mg/ml medium) of purified SAP-precursor9 added to the
culture medium (Fig. 5). The addition of different concentra-
tions of SAP-precursor9 resulted in reduction of the storage of
ceramide, glucosylceramide, and lactosylceramide. The frac-
tion of labeled ceramide, for example, which accounted for 12.8
6 2.0% of total sphingolipid-associated radioactivity in un-
treated SAP-precursor-deficient fibroblasts, decreased to 10.34
6 0.8% or even 1.82 6 0.3% (out of 58,758 dpm/mg of the total
sphingolipid fraction) by administration of 0.025 or 0.9 mg/ml
medium of SAP-precursor9, respectively. In normal cells, cer-
amide made up 1.3 6 0.6% (out of 39,967 dpm/mg) of the total
detectable radioactivity.
In order to demonstrate the same effect on the lipid turnover
for all three purified prosaposins, the [14C]serine pulse-chase
labeling experiment was repeated, adding each SAP-precursor
(0, 6, or 9, 0.5 mg/ml medium of each) to the culture medium of
the deficient fibroblasts during the preincubation and chase
periods (Fig. 6). To evaluate the influence of the material co-
purified with recombinant SAP-precursors, the control frac-
tions from the media of untransfected BHK cells, as described
above, was also offered to labeled mutant fibroblasts. Addition
of all three SAP-precursors decreased the amount of accumu-
lated ceramide, lactosylceramide, and glucosylceramide in
quantitatively similar manner, while no significant influence
on the turnover of these lipids was detectable by the BHK
control fraction (Co).
One known physiological function of SAP-B is to stimulate
the degradation of sulfatide by arylsulfatase A. Since the met-
FIG. 6. Effect of the different SAP-precursor isoforms on the
turnover of labeled sphingolipids in cultured fibroblasts. Fibro-
blasts from a patient with SAP-precursor deficiency and a normal
control (NC) were incubated for 24 h with recombinant SAP-precursor
isoforms purified from the medium of transfected BHK cells (0.5 mg/ml
medium SAP-precursor 0, 6, or 9) and with an equal volume of control
protein fraction isolated from BHK cells transfected with the expression
plasmid pBHE (Co). Subsequently the fibroblasts were incubated for 24
h with [14C]serine (1 mCi/ml). Then the medium was changed, and the
cells chased for 120 h with medium supplemented with unlabeled
serine and with recombinant SAP-precursor 0, 6, or 9 as used in the
preincubation period. After the cell harvest the sphingolipid fraction
was isolated, equal amounts of radioactivities were separated on TLC
and identified as described under “Experimental Procedures.” SM,
sphingomyelin.
FIG. 5. Concentration dependence
of the turnover of labeled sphingolip-
ids in cultured fibroblasts on the
complementation of the culture me-
dium with SAP-precursor9. Fibro-
blasts from a patient with SAP-precursor
deficiency and a normal control (NC) were
incubated for 24 h with medium supple-
mented with recombinant SAP-precur-
sor9 as indicated. Subsequently the cells
were incubated with [14C]serine (1 mCi/
ml) for 24 h. The medium was changed
and the cells were chased for 120 h with a
medium containing unlabeled serine and
the same concentration of recombinant
SAP-precursor9 used during the preincu-
bation period. After harvesting of the
cells, the sphingolipid fraction was iso-
lated, equal amounts of radioactivity were
separated by TLC, and the radioactive
spots identified by autoradiography as
described under “Experimental Proce-
dures.” SM, sphingomyelin.
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abolic labeling of sphingolipids with [14C]serine in cultured
fibroblasts resulted only in the pronounced labeling of those
sphingolipids which are endogenously synthesized in fibro-
blasts, the effect of SAP-B isoforms on the turnover of sulfatide
was determined by loading experiments. [3H]Sulfatide was
added to the medium of the cultured fibroblasts and during the
preincubation and chase periods the culture medium was sup-
plemented with 0.5 mg/ml of each purified SAP-precursor iso-
form. The metabolic fate of the [3H]sulfatide taken up by the
cells was examined by TLC (Fig. 7). While in untreated SAP-
precursor-deficient fibroblasts about 97.6 6 6.0% of the total
radioactivity remained in the accumulated sulfatide, its pro-
portion decreased to 89.2 6 4.1% in the cells treated with each
of the recombinant SAP-precursor isoforms. In contrast, treat-
ment with the control protein fractions (Co) had no effect on
sulfatide turnover. In normal fibroblasts up to 45.2 6 15.7% of
the radioactivity was detectable in the sulfatide fraction.
The presence of the radiolabeled ceramide and sphingomye-
lin, arising from degradation of sulfatide and reutilization of
ceramide in all SAP-deficient fibroblasts cultured in present of
the purified proteins as well as in the normal control clearly
pointed out that all SAP-B isoforms have been able to stimulate
the sulfatide degradation in vivo (Fig. 7).
An analogous feeding experiment was performed with
[3H]globotriaosylceramide in order to examine the function of
all three SAP-B isoforms on the degradation of globotriaosyl-
ceramide (Fig. 8). Due to the fact that the label was located in
the terminal galactose residue, no metabolic products were
detectable. In the normal control cells, the radioactivity of the
isolated globotriaosylceramide constituted 32.2 6 17.5% of to-
tal radioactivity. In the mutant fibroblasts, untreated and
treated with the control protein fractions (Co), globotriaosylce-
ramide bound radioactivity remained 78.9 6 21.8% and 81.9 6
18.1% of the total radioactivity, respectively. In SAP-precursor-
deficient fibroblasts cultured in the presence of purified SAP-
precursor 0, 6, or 9, a decrease of the accumulated globotriao-
sylceramide was generally detectable (62.9 6 11.1% of the total
radioactivity), indicating that all three SAP-B isoforms stimu-
late degradation of globotriaosylceramide to a similar degree.
DISCUSSION
That the SAP-precursor gene is alternatively spliced produc-
ing three different cDNAs, with or without inclusion of 9 or 6
base pairs of exon 8 has been known for several years (14), but
no protein product encoded by the longer cDNAs has been
detected in tissues so far. This can be due to several reasons:
the translation products of the longer cDNAs may be processed
differently and generate different sets of final products, the
longer SAP-B forms may be unstable, or expression pattern of
the sources from which SAP-B was usually purified favors the
protein without the insertion (15). The results presented in this
report indicate that all three polypeptides encoded by the dif-
ferent SAP-precursor cDNAs are transported and processed in
the same manner as described for SAP-precursor in human
fibroblasts and that all three SAP-B isoforms are stable and
have the same sphingolipid activator function (4).
Recently, the relative abundance of the alternatively spliced
mRNA with or without 9 bases was determined by reverse
transcriptase-polymerase chain reaction in various human tis-
sues and cell lines (16), but it was difficult to correlate the
presence of the mRNA forms with the occurrence of mature
SAP-B at the protein level, especially as there are no antibodies
available to differentiate between the three protein forms.
Since we have shown that the maturation of SAP-B proceeds in
a comparable way in BHK cells and in human fibroblasts, the
question arises if there is a significance for the alternative
spliced mRNAs and their protein products. The detection of
immunoprecipitable, stable mature SAP-B derived from the
different SAP-precursors allowed the conclusion that the sta-
bility of mature SAP-B is not affected dramatically by these
FIG. 7.Effect of the SAP-precursor isoforms on themetabolism
of endocytosed [3H]sulfatide. Fibroblasts derived from a patient
with SAP-precursor deficiency and a normal control (NC) were incu-
bated with SAP-precursor 0, 6, or 9 purified from transfected BHK cells
(0.5 mg/ml medium) and an equal volume of BHK cell control protein
fraction (Co) for 24 h. Then the fibroblasts were incubated for 48 h with
[3H]sulfatide (0.288 mCi/ml). Subsequently the cells were chased for 120
h with fresh medium supplemented with the same amount of SAP-
precursor 0, 6, or 9 as used in the preincubation period. The cells were
harvested and the sphingolipid fractions isolated. Radioactivity corre-
sponding to equal amounts of cell protein was separated on TLC and the
spots identified as described under “Experimental Procedures.”
FIG. 8.Effect of the SAP-precursor isoforms on themetabolism
of endocytosed [3H]globotriaosylceramide. Fibroblasts from a pa-
tient with SAP-precursor deficiency and a normal control (NC) were
preincubated with 0.5 mg/ml SAP-precursor 0, 6, or 9 or BHK control
protein (Co) for 24 h. Then the cells were incubated with [3H]globotri-
aosylceramide (GTC) (0.231 mCi/ml) for 48 h. Subsequently the cells
were chased for 120 h with fresh medium supplemented with the same
SAP-precursor 0, 6, or 9 or control protein as used during the preincu-
bation period. After cell harvest the sphingolipid fractions were iso-
lated, radioactivity corresponding to same amounts of cell proteins
separated on TLC and the radioactive spots identified as described
under “Experimental Procedures.”
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insertions. Examination of several patients suffering from ge-
netic SAP-B deficiency demonstrated that disruption of the
correct protein structure of SAP-B led to lack of cross-reacting
material in the tissues or fibroblasts of these patients followed
by an accumulation of sulfatides and globotriaosylceramide (1).
One of these patients had a G777 3 C mutation leading to
substitution of a cysteine residue for a serine (14) and no
mature SAP-B was detectable in patient’s tissue and fibro-
blasts by immunological methods (36). A deletion at the N
terminus of the SAP-B domain due to a splice site mutation in
the prosaposin gene had the same effect (37). In a third case,
the insertion of 33 additional bases by a point mutation intro-
ducing a new splice site at the 59 end of exon 8 resulted in the
insertion of 11 amino acids into the SAP-B region of the SAP-
precursor. No stable SAP-B was released from this precursor
either (38, 39).
The expression studies in BHK cells revealed that the major
part (more than 60%) of the expressed SAP-precursors was
secreted into the culture medium and that a minor amount was
targeted to the acidic organelles of the BHK cells where pro-
teolytic cleavage to the mature SAPs (SAP-A to SAP-D) took
place. An analogous phenomenon was reported for the expres-
sion of cathepsin D precursor in BHK cells and the authors
concluded that if synthesized at a higher rate a particular
group of lysosomal proteins was secreted into the medium
without concomitantly compromising the targeting of other
lysosomal enzymes (40).
Observations that the SAP-precursor occurs in different hu-
man fluids such as milk, cerebrospinal fluid, and seminal
plasma (41, 42) and the fact that all three isoforms were se-
creted into the medium of the transfected BHK cells call for a
detection system for the individual SAP-precursor isoforms.
Such a method would allow determination of the existence and
amounts of the different protein forms in different body fluids.
In addition to findings that demonstrated binding and trans-
port of gangliosides by the SAP-precursor (43), this protein has
been suggested to act as a neuroprotective or regenerative
agent in vivo (44). More recently, the SAP-precursor has been
suggested to be a neurotrophic factor (45), because it elicited
differentiation of neuroblastoma cells when applied in the
nanomolar range. The neurotrophic function is said to be local-
ized on the SAP-C domain (46), indicating that alternative
splicing does not modulate this function.
For our studies on the stimulatory effect of SAP-B on the
lysosomal degradation of sphingolipids we purified the prosa-
posin isoforms from the media of transfected BHK cells. In all
preparations obtained by the purification procedure, partially
processed intermediates copurified with 73-kDa precursor
form. A similar phenomenon was observed during the first
purification steps of SAP-precursor from the medium of in-
fected Sf9 cells, seminal plasma, and milk (29). The interme-
diates were identified to be tri- and disaposins, and a possible
pathway of proteolysis of SAP-precursor was discussed (29).
However, our endocytosis studies demonstrate clearly that all
endocytosed higher protein forms were processed within 24 h to
the mature SAPs (SAP-A to SAP-D). Therefore all effects
shown on lipid degradation (in the time period between 24 and
168 h after feeding of SAP-precursor 0, 6, or 9, see Figs. 4 and
5) were caused by mature SAP forms rather than by the SAP-
precursor or partially processed intermediates.
It has been shown previously that alternative splicing caus-
ing a polymorphism at the protein level may alter the binding
specificity and/or function of the expressed proteins, including
hormone precursors, DNA-binding proteins and structural pro-
teins (47, 48). A recent report indicated that synthetic peptides
derived from the SAP-B amino acid sequence (from Ser246 to
Glu266 with or without the Gln-Asp-Gln insertion) have differ-
ent binding affinities for GM1 ganglioside, sulfatide, and sphin-
gomyelin (16). From these results the authors suggested that
alternative splicing of the SAP-precursor gene may change
binding specificity in the encoded SAP-B presumably to adapt
to the variable sphingolipid composition of tissues. However,
our observations indicate that all SAP-B isoforms are able to
stimulate the degradation of sulfatide and globotriaosylceram-
ide in cultured fibroblasts without significant differences
among them.
Two models have been proposed for the structure of SAP-B.
Potier based his model on sequence homology of SAP-B with
influenza virus neuraminidase (49). The model predicts a high
proportion of b-sheet and one a-helix at the C-terminal end of
SAP-B, which should contain the additional two or three amino
acids inserted by alternative splicing (16). Based on the disul-
fide bonding pattern the second model suggests a four-helix
bundle structure (11, 50). In this model the additional amino
acids would also be placed into a a-helical structure with the
majority of the hydrophobic residues forming a potential lipid
binding core in the interior of the molecule. A mechanism has
been proposed for the interaction of SAP-B with membrane
surfaces and for the binding of single lipid molecules (11). In
this model the helices are oriented parallel to the lipid head
group. After extraction of the lipid from the membrane the
SAP-B helices should create a hydrophobic environment for the
lipid hydrocarbon tail.
Recently, a structural model for a family of proteins called
saposin-like proteins (SAPLIP) was discussed basing on the
four a-helical bundle first proposed by Stevens et al. (50) and
using crystal structural data derived from hemerythrin as a
template for modeling SAP-B (51). In this model the inserted 3
amino acids are located between helices III and IV and might
affect lipid binding directly or indirectly.
All these different models point to the fact that only struc-
tural work on SAP-B and its different isoforms can test the
validity of the above models and may indicate the possible
functional significance of the amino acids insertions.
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